

PCM

PRECISION CANCER MEDICINE


A JOURNAL AIMING TO DELIVER A LASTING BLOW TO CANCER

PCM Annual Report
2021

Editorial Office pcm@amegroups.com





复旦大学附属肿瘤医院
Fudan University Shanghai Cancer Center



Outline of the Report


1. Basic Information
2. Geographic Distribution of Editorial Board Members (2021)
3. Number of Articles Published (2018 - 2021)
4. Different Types of Articles Published (2021)
5. Geographic Distribution of Corresponding Authors (2021)
6. Website Pageviews (2020 vs 2021)
7. Website Pageviews (Results by Year, 2018 - 2021)
8. Website Users (2020 vs 2021)
9. Website Users (Results by Year, 2018 - 2021)
10. Geographic Distribution of Website Users (2021)
11. Most Read Articles in 2021 (Top 10)
12. Special Series (Published & Ongoing)



1. Basic Information

Precision Cancer Medicine (PCM, Precis Cancer Med, ISSN: 2617-2216)

- An open access, peer-reviewed online journal
- Launched in April 2018
- [Accepted for inclusion in Scopus in June 2021](#)
- The official journal of Fudan University Shanghai Cancer Center
- Dedicated to precise diagnosis and treatment of cancers and personalized care for patients
- To explore different kinds of cancers and encompass various areas of oncology, pathology, imaging, radiotherapy, chemotherapy, surgery, anesthesiology, nursing and etc.
- For more information, please visit: <http://pcm.amegroups.com/>



1. Basic Information

Editor-in-Chief

Xiaomao Guo, MD


Professor, Fudan University,
President, Fudan University Shanghai Cancer Center,
President, Shanghai Proton and Heavy Ion Center,
Shanghai, China



Executive Editor-in-Chief

Zhimin Shao, MD

Professor, Fudan University,
Director, Fudan University Cancer Institute and Breast
Cancer Institute,
Fudan University Shanghai Cancer Center,
Shanghai, China




“On behalf of the editorial team, we would like to express our heartfelt appreciation to all the editorial board members, guest editors, reviewers, and authors for your previous support and contributions to the steady growth of PCM in 2021.

In the new year of 2022, we sincerely look forward to your joint efforts in advancing knowledge and research in the field of precision cancer research and improving precise diagnosis and treatment of cancers and personalized care for patients.”


Xiaomao Guo, MD
Editor-in-Chief, PCM

Zhimin Shao, MD
Executive Editor-in-Chief, PCM




2. Geographic Distribution of Editorial Board Members (2021)

Editorial Board Members by Country
% of total: 100% (253 Members from 22 Countries)




PCM has built an internationalized editorial board of 253 members from 22 countries. The largest proportion of editorial board members was from USA (30%), followed by Italy (26%), China (9%) Spain (7%), France (5%), etc.




3. Number of Articles Published (2018 - 2021)

Number of Articles Published per Year




The articles published in PCM have remained stable each year, with a total number of 135 from 2018 to 2021.




4. Different Types of Articles Published (2021)

Shares of Different Article Types
% of total: 100% (40 articles)




A total of 40 articles were published in 2021. The majority of articles was Review Article (57%), followed by Editorial Commentary (22%), Case Report (13%), and Original Article (8%).




5. Geographic Distribution of Corresponding Authors (2021)


Corresponding Authors by Country
% of total: 100% (40 authors from 12 countries)



A total of 40 corresponding authors were identified in 2021. The largest percentage of authors were from USA (32%), followed by Canada (17%), Italy (12%), China (10%), Spain (10%), etc.




6. Website Pageviews (2020 vs 2021)




* On the whole, the monthly website pageviews of 2021 were much larger than the same period of 2020, except for February.

* The average monthly pageview in 2021 reached 6,723, almost double the average number of 3,767 in 2020.

Data collected from Google Analytics on Jan 5, 2022




7. Website Pageviews (Results by Year, 2018 - 2021)




- * Website pageviews have continued to increase from 2018 to 2021, almost double the number every year.
- * The total number of pageviews from 2018 to 2021 has reached 161,668 .

Data collected from Google Analytics on Jan 5, 2022




8. Website Users (2020 vs 2021)




* On the whole, the monthly website users of 2021 were highly above the same period of 2020, except for February.

* The average monthly website users in 2021 reached 2,142, almost double the average number of 1,223 in 2020.

Data collected from Google Analytics on Jan 5, 2022




9. Website Users (Results by Year, 2018 - 2021)



The number of website users has increased remarkably since its launch in 2018, reaching 25,710 in 2021.

Data collected from Google Analytics on Jan 5, 2022




10. Geographic Distribution of Website Users (2021)

Country	Users	Users	Contribution to total:
	24,608 % of Total: 100.00% (24,608)	24,608 % of Total: 100.00% (24,608)	
1. United States	9,182	36.91%	
2. China	2,839	11.41%	
3. India	1,498	6.02%	
4. United Kingdom	1,431	5.75%	
5. Italy	1,195	4.80%	
6. Canada	747	3.00%	
7. Japan	724	2.91%	
8. Spain	462	1.86%	
9. Germany	458	1.84%	
10. South Korea	418	1.68%	

* Totally 24,608 website users from 140 countries were identified in 2021.
* USA was the most represented country with 36.9% of the total users.


Data collected from Google Analytics on Jan 5, 2022



11. Most Read Articles in 2021 (Top 10)

Data collected from Google Analytics on Jan 5, 2022

No.	Article Title	Corresponding Author	Pageviews
1	NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC)	Christian Rolfo (USA)	1656
2	Non-small cell lung cancer PDL1 >50%—should we go single or combo?	Nir Peled (Israel)	1649
3	Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?	Daniel B. Costa (USA)	1324
4	Precision medicine: BRAF mutations in thyroid cancer	Balazs Halmos (USA)	1261
5	Non-small cell lung cancer targetable mutations: present and future	Peter Vu (USA)	1237
6	Alternative non-homologous end joining repair: a master regulator of genomic instability in cancer	Pierfrancesco Tassone (Italy)	710
7	How to recognize and manage hyper-progression and pseudo-progression during immune checkpoint blockade in non-small cell lung cancer	Francesco Facchinetti (France)	575
8	A narrative review of BRAF alterations in human tumors: diagnostic and predictive implications	Lynette M. Sholl (USA)	521
9	Predictive and prognostic implications of microsatellite instability and mismatch repair deficiency in carcinomas of the gastrointestinal tract, liver, and pancreas	Elizabeth Yiru Wu (USA)	486
10	The role of immunotherapy in metastatic triple negative breast cancer: a narrative review of the current clinical trials	Kim Koczka; Nancy Nixon (Canada)	478




12. Special Series (Published in 2021)

[ALK and ROS-1 NSCLC Patients Treatment Approach Based on Genomic Profile by Liquid Biopsy](#)

Jesús Corral (Clínica Universidad de Navarra, Madrid, Spain);
Ernest Nadal (Catalan Institute of Oncology, Barcelona, Spain);
Laura Mezquita (Hospital Clinic, Barcelona, Spain)



JESÚS CORRAL; LAURA MEZQUITA; ERNEST NADAL




12. Special Series (Ongoing)

1) [Predictive and Prognostic Biomarkers in Tumors](#)

Guest Editors:

Mari Mino-Kenudson (Massachusetts General Hospital, USA);


Yin (Rex) P. Hung (Massachusetts General Hospital, USA)



2) [Management of Triple Negative Breast Cancer](#)

Guest Editor:

Jacques Raphael, MD (Western University, Canada)



12. Special Series (Ongoing)

3) [Lung Cancer In Women: From Epidemiology To Therapy](#)

Guest Editors:


Editta Baldini (San Luca Hospital, Italy);

Franca Melfi (University Hospital of Pisa, Italy)



4) [Uncommon Mutations in Non-Small Cell Lung Cancer](#)

Guest Editor: Marco Russano (University Campus Bio-Medico of Rome, Italy)



12. Special Series (Ongoing)

5) [Precision oncology in urogenital and gynecological tumors](#)

Guest Editors:

Elie Rassy (Gustave Roussy Institut, France);


Nicholas Pavlidis (University of Ioannina, Greece);

Stergios Boussios (Medway NHS Foundation Trust, UK);

Joseph Kattan (Saint Joseph University, Lebanon)



ELIE RASSY; NICHOLAS PAVLIDIS; STERGIOS BOUSSIOS; JOSEPH KATTAN



12. Special Series (Ongoing)

6) [How to Detect and Treat NSCLC Patients with Oncogenic Fusions](#)

Guest Editors:

Fabrizio Tabbò (University of Turin, Italy);


Umberto Malapelle (University of Naples Federico II, Italy);

Maria Lucia Reale (University of Turin, Italy);

Angela Listì (University of Turin, Italy)



FABRIZIO TABBÒ; UMBERTO MALAPELLE; MARIA LUCIA REALE; ANGELA LISTÌ



12. Special Series (Ongoing)

7) Quality Assurance in Radiotherapy

Guest Editors:

Paul Van Houtte & Dirk Van Gestel

(Institut Jules Bordet, Université Libre de Bruxelles, Belgium)




8) New Insights in Precision Oncology in Breast Cancer

Guest Editor:

Luca Moscetti (Azienda Ospedaliero-Universitaria di Modena

– Policlinico, Italy)



Our Publisher—

AME Publishing Company

www.amegroups.com

Established in 2009

Registered in Hong Kong

10 offices around the world


60+ peer-reviewed journals

- 13 indexed in SCIE
- 20 indexed in PubMed/PMC/MEDLINE

200+ Medical Books

- 80+ Medical Books in English
- 120+ Medical Books in Chinese

150+ Electronic Editions





Thank you for all your support!

